News + Resources

Keep up with the latest

Featured

This Scientist Is Building Custom Gene-Editing Tools

Scribe Therapeutics Highlights Data Underpinning its Comprehensive Strategy Targeting Key Lipid Drivers of ASCVD at American Heart Association (AHA) Scientific Sessions 2025

November 17, 2025

Scribe Therapeutics Highlights Data Underpinning its Comprehensive Strategy Targeting Key Lipid Drivers of ASCVD at American Heart Association (AHA) Scientific Sessions 2025

November 17, 2025

Epigenetic editors are a gentler form of gene editing

February 24, 2025

The Economist

Epigenetic editors are a gentler form of gene editing

February 24, 2025

CRISPR 2.0, the Next Generation

June 21, 2024

Aspen Ideas: Health

CRISPR 2.0, the Next Generation

June 21, 2024

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

TEDxBerkeley

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

All Stories

News

Scribe, Biogen Partner to Develop Gene Therapy for ALS, Other Neurological Diseases

October 8, 2020

ALS News Today

Read Now

Press Release

Scribe, Biogen Partner to Develop Gene Therapy for ALS, Other Neurological Diseases

October 8, 2020

ALS News Today

Read Now

News

Scribe Therapeutics, Biogen collaborate to develop CRISPR-based genetic medicines

October 7, 2020

Pharmaceutical Business Review

Read Now

Press Release

Scribe Therapeutics, Biogen collaborate to develop CRISPR-based genetic medicines

October 7, 2020

Pharmaceutical Business Review

Read Now

News

Scribe Therapeutics emerges with $20M, Biogen pact to clear CRISPR hurdles

October 7, 2020

Fierce Biotech

Read Now

Press Release

Scribe Therapeutics emerges with $20M, Biogen pact to clear CRISPR hurdles

October 7, 2020

Fierce Biotech

Read Now

News

Starting with Biogen deal in ALS, Scribe planning a new chapter in CRISPR story

October 7, 2020

BioWorld

Read Now

Press Release

Starting with Biogen deal in ALS, Scribe planning a new chapter in CRISPR story

October 7, 2020

BioWorld

Read Now

Press Release

Scribe Therapeutics to Collaborate With Biogen to Develop CRISPR-based Genetic Medicines for Neurological Diseases Including ALS

October 6, 2020

Read Now

Press Release

Scribe Therapeutics to Collaborate With Biogen to Develop CRISPR-based Genetic Medicines for Neurological Diseases Including ALS

October 6, 2020

Read Now

Press Release

Scribe Therapeutics Unveils Fully Integrated Platform for Engineering Breakthrough CRISPR-based Genetic Medicines

October 6, 2020

Read Now

Press Release

Scribe Therapeutics Unveils Fully Integrated Platform for Engineering Breakthrough CRISPR-based Genetic Medicines

October 6, 2020

Read Now

News

CEO of Doudna spinout: Within five years, genome editors will have a 'really big impact' on patients' lives

August 12, 2022

Endpoints News

Read Now

News

Scribe Therapeutics converting an Alameda shipway into a lab

July 30, 2022

The Real Deal

Read Now

News

How Jennifer Doudna's Life Has Changed Since Discovering CRISPR 10 Years Ago

July 1, 2022

TIME

Read Now

News

Innovators Under 35

June 29, 2022

MIT Technology Review

Read Now

News

Scribe Pursues CRISPR Therapies with Expanded Biogen Collaboration

May 12, 2022

Genetic Engineering & Biotechnology News

Read Now

News

Biogen Pursues Another Neuro Target With Scribe

May 4, 2022

Inside Precision Medicine

Read Now

Press release

Scribe Therapeutics Presents Late-Breaking Preclinical Data Supporting STX-1150, a Clinical-Stage Epigenetic Silencing Therapy Designed to Achieve Years of LDL-C Lowering After a Single Dose

May 28, 2026

Read Now

Press release

Scribe Therapeutics Achieves Regulatory Clearance to Initiate First-in-Human Clinical Study of STX-1150 for LDL-C Reduction

May 21, 2026

Read Now

Press release

Scribe Therapeutics Reports Preclinical Data at ASGCT 2026 Demonstrating Enhanced Potency and Specificity of Engineered CRISPR Technologies for Epigenetic Silencing and Gene Editing

May 18, 2026

Read Now

Press release

Scribe Therapeutics to Highlight Engineered CRISPR Platform Advances and Lead Cardiometabolic Pipeline at ASGCT and EAS Congress 2026

April 30, 2026

Read Now

Press release

Scribe Therapeutics Achieves Second Success Milestone for In Vivo Program in Collaboration with Eli Lilly and Company

February 17, 2026

Read Now

Press release

Scribe Therapeutics Projected to Enter the Clinic in Mid-2026 with STX-1150, a PCSK9-targeting CRISPR Epigenetic Silencing Therapy for Durable LDL-C Reduction

January 20, 2026

Read Now

Publications and presentations

Publication

Engineered Allosteric Control Enhances Specificity and Potency of CRISPR-CasX-based Epigenetic Repressors

January 14, 2026

bioRxiv

Read Now

Publication

Single particle charge detection mass spectrometry enables molecular characterization of lipid nanoparticles and mRNA packaging

May 18, 2025

Journal of Controlled Release

Read Now

Publication

CasX enzymes comprise a distinct family of RNA-guided genome editors

February 4, 2019

Nature

Read Now

Publication

Efficient genome editing in the mouse brain by local delivery of engineered Cas9 ribonucleoprotein complexes

May 1, 2017

Nature Biotechnology

Read Now

Publication

Targeted gene knock-in by homology-directed genome editing using Cas9 ribonucleoprotein and AAV donor delivery

March 2, 2017

Nucleic Acids Research

Read Now

Publication

Profiling of engineering hotspots identifies an allosteric CRISPR-Cas9 switch

June 1, 2016

Nature Biotechnology

Read Now

Publication

Multi-reporter selection for the design of active and more specific zinc-finger nucleases for genome editing

January 7, 2016

Nature Communications

Read Now

Publication

Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery

December 15, 2014

eLife

Read Now

Publication

Programmable RNA recognition and cleavage by CRISPR/Cas9

December 11, 2014

Nature

Read Now

Publication

MicroRNA-mediated switching of chromatin-remodelling complexes in neural development

July 30, 2009

Nature

Read Now